Bladder Cancer Weekly

January 13, 2025

Videos

Peer-to-Peer Clinical Conversations

The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist - Cheryl Lee

Cheryl T Lee

Cheryl Lee joins Zachary Klaassen to discuss the top 10 reasons why BCG as monotherapy for bladder cancer will likely cease to exist.

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Félix Guerrero-Ramos

We conducted an analysis of patients diagnosed with MIBC who were either unable or unwilling to undergo curative therapy.

Beyond the Abstracts

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review - Beyond the Abstract

Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer - Beyond the Abstract

Conference Coverage

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

ASTRO 2024: Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)

Physician-Scientist Review Articles

Outcomes of Bladder-Preserving Radiation Therapy in Locally Advanced MIBC - Expert Commentary

The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA.

Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Outcomes of Bladder-Preserving Radiation Therapy in Locally Advanced MIBC - Expert Commentary

Is There a Role for Surgery in the Treatment of Metastatic Urothelial Carcinoma?

Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer.

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.

Towards Reliable Methodology: Microbiome Analysis of Fresh Frozen vs. Formalin-Fixed Paraffin-Embedded Bladder Tissue Samples: A Feasibility Study.

Bowel regimens before radical cystectomy: An analysis of a modern cohort.

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review - Beyond the Abstract

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.

The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary

Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma.

Comprehensive genomic characterization of early-stage bladder cancer.

Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.

Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis - Beyond the Abstract

Long-Term Recurrence Risk, Metastatic Potential and Length of Cystoscopic Surveillance of Low-Grade Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC